Stockscreener 앱 받기
13.64
1.16%
-0.16
전일 마감가:
$13.80
열려 있는:
$13.75
하루 거래량:
738.80K
Relative Volume:
0.51
시가총액:
$1.53B
수익:
$577.74M
순이익/손실:
$-149.78M
주가수익비율:
-9.7429
EPS:
-1.4
순현금흐름:
$-78.21M
1주 성능:
-4.95%
1개월 성능:
+5.49%
6개월 성능:
-17.78%
1년 성능:
-47.58%
1일 변동 폭
$13.50
$14.07
1주일 범위
$13.28
$15.03
52주 변동 폭
$10.70
$27.47
Novocure Ltd Stock (NVCR) Company Profile
명칭
Novocure Ltd
전화
44 (0)15 3475 6700
주소
NO. 4 THE FORUM, ST. HELIER
NVCR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NVCR
Novocure Ltd
|
13.64 | 1.55B | 577.74M | -149.78M | -78.21M | -1.40 |
|
ABT
Abbott Laboratories
|
121.76 | 214.80B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
SYK
Stryker Corp
|
363.78 | 138.62B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
BSX
Boston Scientific Corp
|
88.07 | 133.46B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
MDT
Medtronic Plc
|
96.76 | 126.92B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
84.35 | 49.03B | 5.88B | 1.34B | 799.60M | 2.3489 |
Novocure Ltd Stock (NVCR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-25 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2025-07-08 | 개시 | Ladenburg Thalmann | Buy |
| 2024-12-02 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2024-10-16 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2023-11-20 | 재개 | JP Morgan | Neutral |
| 2023-08-28 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2023-08-08 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2023-08-04 | 개시 | SVB Securities | Outperform |
| 2023-07-31 | 업그레이드 | Evercore ISI | Underperform → In-line |
| 2023-06-07 | 업그레이드 | Wedbush | Underperform → Neutral |
| 2023-05-16 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-03-17 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2023-01-06 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-01-05 | 재확인 | H.C. Wainwright | Buy |
| 2022-11-29 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2022-10-24 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-07-05 | 다운그레이드 | Evercore ISI | In-line → Underperform |
| 2022-05-16 | 개시 | H.C. Wainwright | Buy |
| 2022-02-08 | 개시 | Loop Capital | Buy |
| 2022-02-02 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2022-01-20 | 업그레이드 | Truist | Hold → Buy |
| 2022-01-03 | 업그레이드 | Evercore ISI | Underperform → In-line |
| 2021-07-01 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2021-04-14 | 다운그레이드 | Wedbush | Neutral → Underperform |
| 2021-01-25 | 재확인 | Piper Sandler | Overweight |
| 2020-09-23 | 개시 | Northland Capital | Outperform |
| 2020-09-18 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-09-17 | 다운그레이드 | Truist | Buy → Hold |
| 2020-06-01 | 재개 | Oppenheimer | Perform |
| 2020-05-01 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2020-04-09 | 다운그레이드 | Evercore ISI | In-line → Underperform |
| 2020-03-05 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2020-01-02 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2019-07-29 | 업그레이드 | SunTrust | Hold → Buy |
| 2019-07-26 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2019-07-26 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2019-03-20 | 개시 | SunTrust | Hold |
| 2018-11-02 | 다운그레이드 | Wells Fargo | Outperform → Market Perform |
| 2018-07-16 | 개시 | Evercore ISI | Outperform |
| 2018-04-18 | 재확인 | Mizuho | Buy |
| 2018-02-23 | 재확인 | Mizuho | Buy |
| 2017-05-24 | 업그레이드 | Wells Fargo | Market Perform → Outperform |
| 2016-07-29 | 재확인 | Wedbush | Outperform |
| 2016-01-19 | 개시 | Barclays | Underweight |
| 2015-12-02 | 개시 | Deutsche Bank | Hold |
모두보기
Novocure Ltd 주식(NVCR)의 최신 뉴스
NovoCure Limited (NASDAQ:NVCR) Receives Average Rating of “Hold” from Analysts - Defense World
NovoCure’s (NVCR) “Neutral” Rating Reaffirmed at Wedbush - Defense World
Assessing NovoCure: Insights From 4 Financial Analysts - Benzinga
NovoCure (NVCR) Rating Reiterated as Neutral by Wedbush | NVCR S - GuruFocus
A Look At NovoCure (NVCR) Valuation After Record 2025 Revenue And CEO Transition - simplywall.st
NovoCure (NASDAQ:NVCR) Receives Neutral Rating from Wedbush - MarketBeat
Leerink Partners Maintains Novocure(NVCR.US) With Buy Rating, Cuts Target Price to $24 - 富途牛牛
NovoCure Limited (NASDAQ:NVCR) Receives Average Rating of "Hold" from Analysts - MarketBeat
Brokers Set Expectations for NovoCure FY2030 Earnings - Defense World
HC Wainwright Comments on NovoCure FY2030 Earnings - MarketBeat
NovoCure (NASDAQ:NVCR) Given New $39.00 Price Target at HC Wainwright - Defense World
Is NovoCure (NVCR) A Rare Opportunity After A 45.9% One Year Share Price Fall - simplywall.st
Why NovoCure Is Failing To Disrupt NSCLC (NASDAQ:NVCR) - Seeking Alpha
NovoCure stock holds steady as H.C. Wainwright reiterates Buy rating By Investing.com - Investing.com Nigeria
HC Wainwright & Co. Maintains Buy Rating on NVCR, Lowers Price T - GuruFocus
HC Wainwright Has Lowered Expectations for NovoCure (NASDAQ:NVCR) Stock Price - MarketBeat
NovoCure stock holds steady as H.C. Wainwright reiterates Buy rating - Investing.com
H.C. Wainwright Maintains Novocure(NVCR.US) With Buy Rating, Cuts Target Price to $39 - 富途牛牛
Novocure reports $655 million in preliminary 2025 revenue By Investing.com - Investing.com South Africa
Novocure (NVCR) Surpasses Revenue Expectations with Strong FY25 Performance - GuruFocus
Cancer therapy Novocure hits record sales, awaits 2026 trial results - Stock Titan
Can NovoCure Limited stock double in next 5 years2025 Bull vs Bear & Low Risk High Reward Trade Ideas - Улправда
Will NovoCure Limited stock split attract more investorsProfit Target & Safe Capital Allocation Plans - ulpravda.ru
Can NovoCure Limited stock surprise with earnings upsideEarnings Performance Report & Scalable Portfolio Growth Methods - Улправда
How NovoCure Limited stock reacts to global recession fears2025 Geopolitical Influence & Entry and Exit Point Strategies - ulpravda.ru
How analysts rate NovoCure Limited stock todayMarket Growth Report & Safe Investment Capital Preservation Plans - Улправда
Will NovoCure Limited stock outperform tech sector in 2025Portfolio Growth Summary & Community Verified Watchlist Alerts - Улправда
Total debt per share of NovoCure Ltd. – GETTEX:038 - TradingView — Track All Markets
Voya Investment Management LLC Sells 64,539,786 Shares of NovoCure Limited $NVCR - MarketBeat
NovoCure Ltd (NVCR) Product Pipeline Analysis Report 2025ResearchAndMarkets.com - Bluefield Daily Telegraph
Why NovoCure Limited stock could be next big winnerChart Pattern Recognition & View Live Stock Forecasts Instantly - bollywoodhelpline.com
NovoCure (NVCR): Assessing Valuation After a Recent Rebound From Multi‑Month Lows - Yahoo Finance UK
NovoCure (NVCR): Exploring Valuation After a Recent Share Price Rebound - simplywall.st
Has NovoCure’s Tumor Treating Fields Progress Created a Value Opportunity After the 2025 Share Slump? - Yahoo Finance
Novocure (NVCR) Q2 2025 Earnings Call Transcript - AOL.com
NovoCure (NVCR) Q3 2024 Earnings Call Transcript - The Globe and Mail
First Week of February 2026 Options Trading For NovoCure (NVCR) - Nasdaq
How to hear Novocure’s CEO speak at the J.P. Morgan healthcare event - Stock Titan
NovoCure Limited (NASDAQ:NVCR) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
CapEx per share of NovoCure Ltd. – MUN:038 - TradingView — Track All Markets
Wells Fargo Keeps Their Hold Rating on NovoCure (NVCR) - The Globe and Mail
NovoCure (NVCR): Assessing Valuation After the CEO Transition From Ashley Cordova to Frank Leonard - simplywall.st
NovoCure’s LUNAR-2 Study: A New Horizon in Lung Cancer Treatment - MSN
Does NovoCure’s (NVCR) Internal CEO Transition Reinforce or Recast Its Tumor Treating Fields Strategy? - simplywall.st
Marshall Wace LLP Sells 392,992 Shares of NovoCure Limited $NVCR - MarketBeat
NovoCure (NVCR): Assessing Valuation After a Steep Drawdown and Recent Share Price Uptick - simplywall.st
Does NovoCure's (NVCR) Insider CEO Transition Strengthen Its Long-Term Oncology Strategy Or Limit Change? - Yahoo Finance
NovoCure (NASDAQ:NVCR) Stock Price Up 7%Time to Buy? - MarketBeat
What is the fair value estimate for NovoCure Limited (038) stock in 2025Weekly Trade Report & Verified Stock Trade Ideas - Newser
Edgestream Partners L.P. Increases Holdings in NovoCure Limited $NVCR - Defense World
Is NovoCure’s 93% Five Year Share Price Slide Now Creating an Opportunity in 2025? - Yahoo Finance
Novocure Ltd (NVCR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Novocure Ltd 주식 (NVCR) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Brackmann Christoph | Chief Financial Officer |
Jul 29 '25 |
Buy |
11.59 |
20,000 |
231,800 |
141,150 |
| Stafford Kristin | Director |
Jun 03 '25 |
Sale |
17.28 |
999 |
17,259 |
3,054 |
| LEUNG GABRIEL | Director |
Jun 03 '25 |
Sale |
17.31 |
999 |
17,297 |
81,229 |
| Madden Martin J. | Director |
Jun 03 '25 |
Sale |
17.19 |
999 |
17,176 |
18,674 |
| Scannell Timothy J | Director |
Jun 03 '25 |
Sale |
17.32 |
999 |
17,299 |
6,018 |
| HILLEMAN JERYL L | Director |
Jun 03 '25 |
Sale |
17.26 |
999 |
17,247 |
5,591 |
| Ocean Allyson J | Director |
Jun 03 '25 |
Sale |
17.29 |
999 |
17,269 |
3,054 |
| VERNON W ANTHONY | Director |
Jun 03 '25 |
Sale |
17.35 |
999 |
17,329 |
167,887 |
| Hung David | Director |
Jun 03 '25 |
Sale |
17.30 |
999 |
17,280 |
12,195 |
| Leonard Frank X | EVP, Pres., Novocure Oncology |
Jun 02 '25 |
Sale |
17.50 |
30,196 |
528,413 |
168,452 |
0.42%
1.96%
자본화:
|
볼륨(24시간):